Immunotherapy

Papers
(The H4-Index of Immunotherapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study94
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma69
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study51
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy36
Imaging of brain metastases treated with immune checkpoint inhibitors33
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study32
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma29
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia28
Postvaccination immune-mediated hepatitis: what do we really know?26
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15822
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data21
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review21
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis19
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas18
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?18
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis17
0.26225805282593